Medable Expands Leadership Team to Drive Growth and Adoption of Decentralized Clinical Trials
Summary
Medable recently announced strong momentum in the first half of 2020, as pharma and biotech companies shift clinical trials to digital platforms in response to COVID-19. Medable is driving innovation and adoption globally for decentralized trials, expanding access with direct-to-patient technologies across therapeutic areas. Medable’s platform has been used for trials across a broad range of therapeutic areas, including oncology, dermatology, neurology, endocrinology and antivirals. “We’re thrilled to add more smart, experienced and driven leaders to work closely with our pharma and biotech customers and partners around the world,” said Dr. Michelle Longmire, CEO and co-founder of Medable. “While COVID-19 has clearly accelerated the shift to decentralized trials, we expect the pace to continue as digital platforms become a foundation for all trials—making them much more accessible for patients while cutting the time it takes to bring innovative therapies to market.” Medable has recruited a diverse and experienced team of digital and biopharma experts globally, with multiple U.S. offices including its Palo Alto headquarters, and global offices in Europe and South America.